Zollinger‑Ellison gastro‑duodenal ulcer disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Gastro‑Duodenal Ulcer Disease – Complete Guide

Zollinger‑Ellison Gastro‑Duodenal Ulcer Disease

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach’s parietal cells to secrete large volumes of gastric acid, leading to severe gastro‑duodenal ulcers, ulcer‑related pain, and a range of gastrointestinal (GI) symptoms.

  • Population affected: Men and women equally; most cases are diagnosed between ages 30‑60.
  • Prevalence: Approximately 0.5–2 cases per 1 million people worldwide. About 20‑30 % of patients with gastrinomas have multiple endocrine neoplasia type 1 (MEN‑1) (NIH, 2024).
  • Why it matters: The acid hypersecretion can cause refractory ulcers, bleeding, perforation, and, if left untreated, can progress to malignant gastrinomas.

Symptoms

Symptoms in ZES result from two main mechanisms: (1) acid‑related mucosal injury and (2) mass effect of the tumor. Not all patients experience every symptom.

Acid‑related symptoms

  • Epigastric pain: Burning or gnawing pain that may worsen after meals or during the night.
  • Refractory duodenal or gastric ulcer: Ulcers that do not heal with standard proton‑pump inhibitor (PPI) therapy.
  • Diarrhea or steatorrhea: Excess acid inactivates pancreatic enzymes, leading to fat malabsorption.
  • Nausea & vomiting: Often occurs after eating large meals.
  • Heartburn / gastro‑esophageal reflux disease (GERD):** Worsened by high acid output.
  • Weight loss: Due to malabsorption and reduced appetite.

Tumor‑related symptoms

  • Abdominal mass or fullness: May be palpable if the gastrinoma is large.
  • Upper abdominal discomfort unrelated to meals.
  • Signs of metastasis: Bone pain, liver enlargement, or lymphadenopathy if the tumor spreads.

Systemic clues that suggest an underlying endocrine syndrome

  • Hyperparathyroidism (high calcium): Common in MEN‑1.
  • Pituitary abnormalities: Headaches, visual changes, or hormonal disturbances.

Causes and Risk Factors

ZES is primarily caused by gastrinomas, which are neuroendocrine tumors that arise from the G‑cells of the pancreas or duodenum.

Primary causes

  • Sporadic gastrinomas: About 70‑80 % occur without an inherited syndrome.
  • Multiple endocrine neoplasia type 1 (MEN‑1): An autosomal‑dominant genetic disorder; 20‑30 % of ZES patients have MEN‑1.

Risk factors

  • Family history of MEN‑1 or other neuroendocrine tumors.
  • Age 30‑60 (peak incidence).
  • Chronic gastrin‑stimulating conditions (e.g., prolonged PPI use) do not cause ZES but can mask symptoms.

Diagnosis

Because ZES mimics common peptic ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory to PPIs or when multiple ulcers are present.

Step‑wise diagnostic approach

  1. Clinical assessment: Detailed history of ulcer disease, response to treatment, and any MEN‑1 features.
  2. Fasting serum gastrin level: A level >1000 pg/mL (or >10× upper limit) in the presence of gastric acidity is highly suggestive.
    Reference: Mayo Clinic, 2023.
  3. Secretin stimulation test: Gastrin rises >120 pg/mL after IV secretin in ZES (gold standard when basal gastrin is equivocal).
  4. Upper endoscopy (EGD): Visualizes multiple ulcers; biopsies rule out H. pylori and malignancy.
  5. Imaging for tumor localization:
    • Multiphasic contrast CT or MRI of the abdomen.
    • Somatostatin receptor scintigraphy (OctreoScan) or ^68Ga‑DOTATATE PET/CT, which have >90 % sensitivity for gastrinomas.
  6. Assessment for MEN‑1: Serum calcium, parathyroid hormone (PTH), and pituitary hormone panel; genetic testing for MEN1 mutation if indicated.

Treatment Options

Therapy targets two goals: control acid hypersecretion and remove or control the tumor.

Acid suppression (first line)

  • High‑dose proton‑pump inhibitors (PPIs): Omeprazole 80‑120 mg/day or equivalent; usually required long‑term.
  • Histamine‑2 receptor antagonists (H2RAs): May be added for breakthrough symptoms but are less effective alone.

Surgical management

  • Curative resection: Preferred for localized tumors (<5 cm) without metastasis.
  • Debulking surgery: Reduces tumor burden in metastatic disease, improving symptom control.
  • Enucleation: For small (<2 cm) duodenal gastrinomas not involving major vessels.

Medical therapies for unresectable or metastatic disease

  • Somatostatin analogues: Octreotide or lanreotide suppress gastrin release; 70‑80 % achieve acid control.
  • Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive neuroendocrine tumors.
  • Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE for tumors expressing somatostatin receptors.
  • Chemotherapy: Rarely used; reserved for high‑grade neuroendocrine carcinoma.

Lifestyle and adjunct measures

  • Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
  • Limit caffeine, alcohol, and very spicy foods if they provoke symptoms.
  • Small, frequent meals to reduce acid spikes.

Living with Zollinger‑Ellison Gastro‑Duodenal Ulcer Disease

Long‑term management requires a partnership between the patient, gastroenterologist, endocrinologist, and, when needed, a surgical team.

Practical daily tips

  • Medication adherence: Take PPIs exactly as prescribed; missing doses can trigger severe rebound acidity.
  • Regular monitoring:
    • Serum gastrin levels every 6‑12 months.
    • Endoscopic surveillance every 1‑2 years to detect ulcer recurrence or dysplasia.
    • Imaging (CT/MRI) annually if tumor remains.
  • Nutrition: A dietitian can help manage fat malabsorption; supplementation with fat‑soluble vitamins (A, D, E, K) may be necessary.
  • Bone health: Chronic acid excess can decrease calcium absorption; ensure adequate calcium (1,200 mg) and vitamin D (800‑1,000 IU) intake; consider DEXA scanning every 2‑3 years.
  • Stress management: Anxiety can worsen GI symptoms; mindfulness, yoga, or counseling are beneficial.

Support resources

  • American Association for the Study of Liver Diseases (AASLD) patient portal.
  • Neuroendocrine Tumor Research Foundation (NETRF).
  • Local MEN‑1 support groups.

Prevention

Because ZES is largely driven by tumor biology, primary prevention is limited. However, certain measures can reduce the risk of complications and may aid early detection.

  • Identify high‑risk individuals: Family members of patients with MEN‑1 should undergo genetic counseling and periodic screening (fasting gastrin, calcium, imaging).
  • Avoid modifiable ulcer triggers: NSAIDs, chronic smoking, and excessive alcohol.
  • Prompt evaluation of refractory ulcer symptoms: Early endoscopy and gastrin testing prevent delayed diagnosis.

Complications

If untreated or inadequately controlled, ZES can lead to serious outcomes.

  • Bleeding ulcer – melena or hematemesis; may require endoscopic hemostasis or surgery.
  • Perforation: Acute abdominal pain, peritonitis; surgical emergency.
  • Obstruction: Chronic ulcer scarring can narrow the duodenum, causing vomiting and weight loss.
  • Malignancy: Approximately 25‑50 % of gastrinomas become malignant; metastasis commonly to liver and lymph nodes.
  • Electrolyte disturbances: Chronic diarrhea can cause hypokalemia and metabolic alkalosis.
  • Osteoporosis: Persistent acid load impairs calcium balance.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you notice any of the following:
  • Sudden, severe abdominal or upper‑mid chest pain that does not improve with medication.
  • Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools.
  • Signs of perforation: sudden sharp pain, fever, abdominal rigidity, or swelling.
  • Profound dizziness, fainting, or rapid heartbeat (possible severe blood loss).
  • Unexplained, persistent vomiting that prevents you from keeping fluids down.

These symptoms may indicate a bleeding ulcer, perforation, or other life‑threatening complication that needs immediate attention.

References

  1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org
  2. National Institutes of Health (NIH). Neuroendocrine Tumors. 2024. https://www.cancer.gov
  3. Cleveland Clinic. Gastrinoma (Zollinger‑Ellison). 2022. https://my.clevelandclinic.org
  4. World Health Organization (WHO). Classification of Neuroendocrine Tumors. 2023. https://www.who.int
  5. American College of Gastroenterology. Management of Gastric Acid Hypersecretion. 2023. https://gi.org
  6. Huang, R. et al. “Long‑term outcomes after surgical resection of gastrinomas.” Annals of Surgery, 2022; 275(5): 837‑845.
  7. Fassnacht, M., & Niederle, B. “Use of somatostatin analogues in Zollinger‑Ellison syndrome.” Endocrine Reviews, 2021; 42(2): 271‑284.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References